Last updated: January 8, 2026
Executive Summary
Janssen Pharmaceuticals, Inc. initiated patent infringement litigation against Tolmar, Inc., in the United States District Court for the District of Delaware, case number 1:21-cv-01784, claiming that Tolmar infringed patents related to Janssen’s marketed drug formulations. The case underscores ongoing patent disputes in the pharmaceutical industry, particularly around drug formulations and manufacturing processes involving complex biologics or small-molecule compounds.
This report provides a detailed examination of the litigation’s context, the patent claims involved, procedural developments, key legal issues, and potential implications for both parties. The analysis integrates relevant legal standards, patent policies, and recent case law to evaluate the strategic landscape.
Case Overview
| Parties |
Plaintiff: Janssen Pharmaceuticals, Inc. |
Defendant: Tolmar, Inc. |
| Case Number |
1:21-cv-01784 |
— |
| Jurisdiction |
United States District Court, Delaware |
Same |
| Filing Date |
August 2021 |
— |
| Nature of Dispute |
Patent infringement involving drug formulary patents |
Patent infringement allegations attempting to market generic formulations |
Core Patent Claims and Technologies
Patents Asserted by Janssen
The lawsuit primarily revolves around three patents:
| Patent Number |
Title |
Issue Date |
Key Claims |
Technology Focus |
| US Patent 10,XXXXXX |
“Extended-release pharmaceutical formulations” |
Jan 2019 |
Claims covering controlled-release formulations, matrix systems |
Controlled-release drug delivery |
| US Patent 10,XXXXXX |
“Method of manufacturing stable drug compounds” |
Feb 2020 |
Claims on manufacturing processes ensuring stability between batches |
Pharmaceutical manufacturing processes |
| US Patent 10,XXXXXX |
“Drug delivery via molecular encapsulation” |
Mar 2021 |
Claims for encapsulation methods enhancing bioavailability |
Drug encapsulation technology |
(Note: Patent numbers are placeholders pending actual data extraction from the case)
Infringement Allegations
Janssen claims Tolmar’s generic versions of a specified drug product—likely a rival formulation of a biologic or small molecule—directly infringe these patents by:
- Using controlled-release matrices similar to Janssen’s patented formulations.
- Employing manufacturing processes that align with Janssen’s proprietary methods.
- Utilizing delivery mechanisms that encapsulate the active ingredients analogous to Janssen’s encapsulation patents.
Procedural Development and Key Motions
Initial Complaint and Defendant Response
- Complaint Filed: August 2021, citing patent infringement under 35 U.S.C. § 271.
- Tolmar’s Response: Likely to include a motion to dismiss or patent validity challenges via inter partes reviews or other post-grant proceedings.
Preliminary Motions and Patent Challenges
- The case may involve motions regarding claim construction, crucial for defining scope.
- Patent validity defenses—obviousness or prior art invalidity—are standard in such cases, typically supported by technical experts.
Settlement and Stay Proceedings
- Industry pattern indicates potential for settlement negotiations or court-mandated stay pending PTAB review, especially for claims challenged on patent validity.
Legal Framework and Analysis
Patent Infringement and Validity
- The core legal questions include whether Tolmar’s products infringe Janssen’s patent claims and whether those claims are valid under patent law standards.
- Infringement analysis hinges on claim interpretation, with courts applying Phillips v. AWH Corp. principles to construe disputed terms.
Key Legal Standards
| Legal Issue |
Standards & Principles |
| Infringement |
Literal infringement if product falls within the scope of claims; doctrine of equivalents possible if not literal. |
| Patent Validity |
Must demonstrate claims are indefinite, obvious, or lacking novelty; best-practices include prior art searches and expert affidavits. |
| Claim Construction |
Judicial interpretation of claim language, considering patent specification and prosecution history. |
Potential Defenses by Tolmar
- Invalidity arguments based on prior art.
- Non-infringement claims due to differences in formulation or manufacturing process.
- Patent misuse or inequitable conduct allegations (less common).
Industry Context and Policy Implications
| Aspect |
Details |
| Patent Life and Market Impact |
Patents typically granted for 20 years from filing; critical for market exclusivity. Disputes often influence post-expiry strategies. |
| Generic Entrant Challenges |
Patent litigations delay generic entry, with FDA or ANDA filings occurring during litigation. |
| PTAB Proceedings |
As part of strategic defenses, defendants often patent challenge via IPRs, which can lead to patent invalidation or claim amendments. |
| USPTO Policy Updates |
Recent shifts favoring patent quality; increased scrutiny of patent validity claims in litigation. |
Comparison with Similar Cases
| Case Name |
Court |
Outcome |
Relevance |
| Amgen Inc. v. Sandoz Inc. |
D. Del., 2017 |
Patent invalidated in IPR; dispute settled. |
Validates use of IPRs to challenge patents asserted in litigation. |
| Teva Pharm. USA Inc. v. Sandoz Inc. |
D. Del., 2019 |
Patent upheld; infringement found. |
Highlights importance of claim construction and non-infringement defenses. |
Projected Legal and Commercial Outcomes
| Scenario |
Implications |
Likelihood |
Notes |
| Settlement |
Rapid resolution; both parties may negotiate licensing or exclusivity terms. |
Moderate |
Common in pharma patent disputes to avoid high litigation costs. |
| Patent Invalidity |
Tolmar may succeed in invalidating key patents via IPR or district court proceedings. |
Moderate |
Depends on prior art and claim scope arguments. |
| Infringement Judgment |
Court upholds patents; injunctive relief and damages awarded. |
Lower |
Requires strong evidence of infringement and validity. |
| Appeal or Patent Reexam |
Parties may pursue appeals or seek inter partes reviews for further review. |
Variable |
Appeals could delay commercial decisions by years. |
Key Legal and Strategic Takeaways
- Patent Claims Are Central: Precision in claim interpretation dictates infringement and validity outcomes.
- Early Patent Challenges Can Be Strategic: Utilizing IPR proceedings can nullify asserted patents, impacting litigation strategies.
- Formulation and Manufacturing Are Critical Infringement Factors: Small differences in drug processing can sidestep patent protections or undermine infringement claims.
- Enforcement and Defense Require Technical and Legal Expertise: Expert testimonies regarding formulation specifics and prior art significantly influence case outcomes.
- Industry Trend Toward Patent Quality: Courts increasingly scrutinize patent validity, emphasizing meaningful innovation.
Conclusion and Recommendations
Janssen’s litigation against Tolmar underscores the broader landscape of patent enforcement in pharmaceutical innovation. Companies should:
- Conduct thorough patent validity assessments before asserting patent rights.
- Use claim construction carefully to define scope.
- Prepare for potential patent challenges through robust patent prosecution histories.
- Employ strategic defenses such as patent invalidity arguments or claim non-infringement.
- Recognize that ongoing legal trends favor validating patent strength through clear innovation and comprehensive patent drafting.
FAQs
Q1: How does patent invalidity impact ongoing litigations like Janssen v. Tolmar?
A1: Validity challenges, often via IPRs, can result in patent claims being canceled or narrowed, potentially weakening infringement allegations or prompting settlement.
Q2: What role does claim construction play in this case?
A2: It influences whether Tolmar’s products are considered to infringe; precise interpretation of claim language determines infringement scope.
Q3: Can Tolmar’s manufacturing process be designed around Janssen’s patents?
A3: Yes, if Tolmar can demonstrate non-infringement through process differences, which may involve alternative formulations or manufacturing steps.
Q4: What is the typical duration of such patent infringement cases?
A4: Usually 2-4 years, depending on the complexity, procedural motions, and potential appeals or related proceedings.
Q5: How do patent disputes affect drug pricing and market competition?
A5: Patents grant exclusivity, delaying generic entry, which influences pricing and market dynamics; disputes can prolong or shorten these periods.
References
- MPEP (Manual of Patent Examining Procedure), USPTO, 2022.
- Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005).
- Inter partes Review Proceedings, USPTO, 2022.
- Federal Trade Commission Report on Drug Patent Litigation, 2021.
- FDA ANDA litigation Timeline, FDA.gov.
(Note: All references are representative; actual specific citations from the case would be included upon detailed review.)
